iPSC technology-Powerful hand for disease modeling and therapeutic screen

키워드

참고문헌 (78)

1. Rajamohan D, "Current status of drug screening and disease modelling in human pluripotent stem cells", Bioessays, 35, pp.281~298 (2013)
2. Rubin LL, "Stem cell biology and drug discovery", BMC Biol, 9, pp.42~ (2011)
3. Seok J, "Genomic responses in mouse models poorly mimic human inflammatory diseases", Proc Natl Acad Sci U S A, 110, pp.3507~3512 (2013)
4. Munos B, "Lessons from 60 years of pharmaceutical innovation", Nat Rev Drug Discov, 8, pp.959~968 (2009)
5. Park IH, "Disease-specific induced pluripotent stem cells", Cell, 134, pp.877~886 (2008)
6. Takahashi K, "Induction of pluripotent stem cells from adult human fibroblasts by defined factors", Cell, 131, pp.861~872 (2007)
7. Takahashi K, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors", Cell, 126, pp.663~676 (2006)
8. Ban H, "Efficient generation of transgene-free human induced pluripotent stem cells(iPSCs)by temperature-sensitive Sendai virus vectors", Proc Natl Acad Sci U S A, 108, pp.14234~14239 (2011)
9. 김창성, "Disease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe application", Blood Research, 49(1), pp.7~14 (2014), 대한혈액학회
10. Mercola M, "Cardiac muscle regeneration: lessons from development", Genes Dev, 25, pp.299~309 (2011)
11. Nascone N, "An inductive role for the endoderm in Xenopus cardiogenesis", Development, 121, pp.515~523 (1995)
12. Kim C, "Non-cardiomyocytes influence the electrophysiological maturation of human embryonic stem cell-derived cardiomyocytes during differentiation", Stem Cells Dev, 19, pp.783~795 (2010)
13. Filipczyk AA, "Regulation of cardiomyocyte differentiation of embryonic stem cells by extracellular signalling", Cell Mol Life Sci, 64, pp.704~718 (2007)
14. Yang L, "Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population", Nature, 453, pp.524~528 (2008)
15. Lian X, "Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling", Proc Natl Acad Sci U S A, 109, pp.1848~1857 (2012)
16. Moretti A, "Patient-specific induced pluripotent stem-cell models for long-QT syndrome", N Engl J Med, 363, pp.1397~1409 (2010)
17. Itzhaki I, "Modelling the long QT syndrome with induced pluripotent stem cells", Nature, 471, pp.225~229 (2011)
18. Yazawa M, "Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome", Nature, 471, pp.230~234 (2011)
19. Ruan Y, "Therapeutic strategies for long-QT syndrome: does the molecular substrate matter?", Circ Arrhythm Electrophysiol, 1, pp.290~297 (2008)
20. Terrenoire C, "Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics", J Gen Physiol, 141, pp.61~72 (2013)
21. Moreno JD, "Pathophysiology of the cardiac late Na current and its potential as a drug target", J Mol Cell Cardiol, 52, pp.608~619 (2012)
22. Carvajal-Vergara X, "Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome", Nature, 465, pp.808~812 (2010)
23. Lan F, "Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells", Cell Stem Cell, 12, pp.101~113 (2013)
24. Tabar V, "Pluripotent stem cells in regenerative medicine: challenges and recent progress", Nat Rev Genet, 15, pp.82~92 (2014)
25. Zhang SC, "In vitro differentiation of transplantable neural precursors from human embryonic stem cells", Nat Biotechnol, 19, pp.1129~1133 (2001)
26. Reubinoff BE, "Neural progenitors from human embryonic stem cells", Nat Biotechnol, 19, pp.1134~1140 (2001)
27. Chambers SM, "Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling", Nat Biotechnol, 27, pp.275~280 (2009)
28. Kondo T, "Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness", Cell Stem Cell, 12, pp.487~496 (2013)
29. Yagi T, "Modeling familial Alzheimer's disease with induced pluripotent stem cells", Hum Mol Genet, 20, pp.4530~4539 (2011)
30. Wang H, "Induced pluripotent stem cells to model and treat neurogenetic disorders", Neural Plast, 2012, pp.346053~ (2012)
31. Israel MA, "Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells", Nature, 482, pp.216~220 (2012)
32. Brennand KJ, "Modelling schizophrenia using human induced pluripotent stem cells", Nature, 473, pp.221~225 (2011)
33. Ryan SD, "Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription", Cell, 155, pp.1351~1364 (2013)
34. Kaye JA, "Modeling Huntington's disease with induced pluripotent stem cells", Mol Cell Neurosci, 56, pp.50~64 (2013)
35. Jeon I, "Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells", Stem Cells, 30, pp.2054~2062 (2012)
36. Zhang K, "Huntington's disease: dancing in a dish", Cell Res, 22, pp.1627~1630 (2012)
37. Williams EC, "Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons", Hum Mol Genet, 23, pp.2968~2980 (2014)
38. Jeon I, "In Vivo Roles of a Patient-Derived Induced Pluripotent Stem Cell Line(HD72-iPSC)in the YAC128 Model of Huntington's Disease", Int J Stem Cells, 7, pp.43~47 (2014)
39. Yang J, "Induced pluripotent stem cells can be used to model the genomic imprinting disorder Prader-Willi syndrome", J Biol Chem, 285, pp.40303~40311 (2010)
40. Dajani R, "Investigation of Rett syndrome using pluripotent stem cells", J Cell Biochem, 114, pp.2446~2453 (2013)
41. Ananiev G, "Isogenic pairs of wild type and mutant induced pluripotent stem cell(iPSC)lines from Rett syndrome patients as in vitro disease model", PLoS One, 6, pp.e25255~ (2011)
42. Schöndorf DC, "iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis", Nat Commun, 5, pp.4028~ (2014)
43. Chamberlain SJ, "Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes", Proc Natl Acad Sci U S A, 107, pp.17668~17673 (2010)
44. Sareen D, "Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy", PLoS One, 7, pp.e39113~ (2012)
45. Egawa N, "ALS disease modeling and drug screening using patient-specific iPS cells", Rinsho Shinkeigaku, 53, pp.1020~1022 (2013)
46. Corti S, "Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy", Sci Transl Med, 4, pp.165ra162~ (2012)
47. Ross CA, "Human-induced pluripotent stem cells: potential for neurodegenerative diseases", Hum Mol Genet, 23, pp.17~26 (2014)
48. Kiskinis E, "Pathways Disrupted in Human ALS Motor Neurons Identified through Genetic Correction of Mutant SOD1", Cell Stem Cell, 14, pp.781~795 (2014)
49. Chen H, "Modeling ALS with iPSCs Reveals that Mutant SOD1 Misregulates Neurofilament Balance in Motor Neurons", Cell Stem Cell, 14, pp.796~809 (2014)
50. Wolstencroft EC, "A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels", Hum Mol Genet, 14, pp.1199~1210 (2005)
51. Makhortova NR, "A screen for regulators of survival of motor neuron protein levels", Nat Chem Biol, 7, pp.544~552 (2011)
52. Guo X, "Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration", J Clin Invest, 123, pp.5371~5388 (2013)
53. Charbord J, "High throughput screening for inhibitors of REST in neural derivatives of human embryonic stem cells reveals a chemical compound that promotes expression of neuronal genes", Stem Cells, 31, pp.1816~1828 (2013)
54. Miller JD, "Human iPSC-based modeling of late-onset disease via progerin-induced aging", Cell Stem Cell, 13, pp.691~705 (2013)
55. Kim C, "Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs", Nature, 494, pp.105~110 (2013)
56. Reinhardt P, "Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression", Cell Stem Cell, 12, pp.354~367 (2013)
57. Lopaschuk GD, "Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation", J Cardiovasc Pharmacol, 56, pp.130~140 (2010)
58. Djouadi F, "A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy", Cardiovasc Res, 84, pp.83~90 (2009)
59. Eroshenko N, "Effect of substrate stiffness on early human embryonic stem cell differentiation", J Biol Eng, 7, pp.7~ (2013)
60. Engler AJ, "Embryonic cardiomyocytes beat best on a matrix with heartlike elasticity: scar-like rigidity inhibits beating", J Cell Sci, 121, pp.3794~3802 (2008)
61. Galie PA, "Substrate stiffness affects sarcomere and costamere structure and electrophysiological function of isolated adult cardiomyocytes", Cardiovasc Pathol, 22, pp.219~227 (2013)
62. Choi SM, "Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells", Hepatology, 57, pp.2458~2468 (2013)
63. Hidvegi T, "An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis", Science, 329, pp.229~232 (2010)
64. Höing S, "Discovery of inhibitors of microglial neurotoxicity acting through multiple mechanisms using a stem-cell-based phenotypic assay", Cell Stem Cell, 11, pp.620~632 (2012)
65. Yang YM, "A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS", Cell Stem Cell, 12, pp.713~726 (2013)
66. Fermini B, "The impact of drug-induced QT interval prolongation on drug discovery and development", Nat Rev Drug Discov, 2, pp.439~447 (2003)
67. Zeevi-Levin N, "Cardiomyocytes derived from human pluripotent stem cells for drug screening", Pharmacol Ther, 134, pp.180~188 (2012)
68. De Bruin ML, "Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death", Eur Heart J, 26, pp.590~597 (2005)
69. Liang P, "Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity", Circulation, 127, pp.1677~1691 (2013)
70. Grant AO, "Cardiac ion channels", Circ Arrhythm Electrophysiol, 2, pp.185~194 (2009)
71. Knollmann BC, "Induced pluripotent stem cell-derived cardiomyocytes: boutique science or valuable arrhythmia model?", Circ Res, 112, pp.969~976 (2013)
72. Musunuru K, "Genome editing of human pluripotent stem cells to generate human cellular disease models", Dis Model Mech, 6, pp.896~904 (2013)
73. Kim H, "A guide to genome engineering with programmable nucleases", Nat Rev Genet, 15, pp.321~334 (2014)
74. Maeder ML, "CRISPR RNA-guided activation of endogenous human genes", Nat Methods, 10, pp.977~979 (2013)
75. Qiang L, "Remodeling neurodegeneration: somatic cell reprogramming-based models of adult neurological disorders", Neuron, 78, pp.957~969 (2013)
76. Wada R, "Induction of human cardiomyocyte-like cells from fibroblasts by defined factors", Proc Natl Acad Sci U S A, 110, pp.12667~12672 (2013)
77. Fu JD, "Direct Reprogramming of Human Fibroblasts toward a Cardiomyocyte-like State", Stem Cell Reports, 1, pp.235~247 (2013)
78. Cerrone M, "Missense mutations in plakophilin-2 cause sodium current deficit and associate with a brugada syndrome phenotype", Circulation, 129, pp.1092~1103 (2014)

관련 논문AI추천